MindFuel Blog

Australia Leads the Way with World-First Psychedelic Therapy In a groundbreaking move earlier this year, Australia's medicines regulator made a landmark decision to approve the use of psychedelics for therapeutic purposes. The decision allows for the use of psilocybin, found in magic mushrooms, to treat treatment-resistant depression and MDMA (commonly known as ecstasy) for post-traumatic stress disorder (PTSD). This decision,...

Unlocking the Therapeutic Potential of Psilocybin: Insights from Dr. Andrew Huberman's Latest Podcast Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. It has been used for centuries in various spiritual and cultural contexts, but in recent years, it has gained attention for its therapeutic potential in treating mental health disorders such as depression, anxiety, and...

In collaboration with the most progressive marae he could find, entrepreneur Manu Caddie has been investigating the potential of Weraroa (Psilocybe weraroa), an indigenous magic mushroom known to contain psilocybin, to support Whanau addicted the meth (methamphetamine, speed, P).

"How To Change Your Mind" is officially streaming on Netflix!Author Michael Pollan leads the way in this docuseries exploring the history and uses of psychedelics, including LSD, psilocybin, MDMA and mescaline.This important docu-series based on the best-selling book by Michael Pollan, brings even more focus to the exciting psychedelic renaissance we are living in.You can watch the trailer below:

An analysis of a large international drug survey suggests that psilocybin, one of the active ingredients in Magic Mushrooms is a relatively safe drug, with only 0.2% of magic mushroom users having sought emergency medical care after use. The findings, published in the Journal of Psychopharmacology, further suggest that such adverse incidents are most often psychological in nature and resolved within 24...

British start up Clerkenwell Health have opened Europe's first commercial facility for psychedelic drug trials with the goal of making the United Kingdom a global leader in psychedelic research and innovation.They aim to begin clinical trials at their central London facility in August, initially focusing on psilocybin for anxiety associated with diagnoses of terminal illness. Here at MindFuel we wish...

Auckland scientists would like to dose advanced-stage cancer patients with mico-doses of the psychedelic drug LSD.Lead researcher, Lisa Reynolds, a health psychologist from Auckland University, explained to First Up that LSD could offer the patients a cognitive pathway to reduce anxiety around dying and allow them to connect with what was important to them.She says "The research I've seen so far...

This year, four Australian institutions will start recruiting for separate research into using psilocybin and MDMA for PTSD, addiction, depression and anxiety.Edith Cowan and Monash universities will begin separate trials into the potential for MDMA to treat post-traumatic stress disorder. St Vincent's Hospital Sydney will examine the impact of psilocybin on preventing methamphetamine relapse, Monash will study its effect on...

Watch "Magic Molecules," Bloomberg Quicktake's new investigative report about psychedelic science, featuring educational interviews with MAPS Founder Rick Doblin, Ph.D., and other researchers. WATCH ONLINE HERE Sources: MAPs, Bloomberg quicktake.

Less than two years ago, the amazing scientists at the Johns Hopkins Psychedelic Research Unit began studying the effects of Psilocybin, one of the main psychoactive substances found in magic mushrooms. The preliminary results are out: 83% of their participants showed a clinically significant reduction in depression symptoms 53% met criteria for remission. Stay tuned for the results of their...

The latest episode (#377) of the Tim Ferris show features a panel that Tim moderated in front of a standing-room-only crowd at the Milken Institute’s Global Conference 2019. It includes a great overview of psychedelic science, investing opportunities, anecdotal personal benefits, legal challenges, and much more. Tim thinks that this is one of the more comprehensive panels ever done on the...

The worlds' first formal center for psychedelic research will launch at Imperial College London today. Funded by more than £3 million from 5 founding donors, the new Imperial Center for Psychedelic Research will build on over a decades pioneering work in this area carried out at Imperial, including a clinical trial that has kick-started the global efforts to develop psilocybin...

DMT (N,N-dimethyltryptamine) is a potent endogenous psychedelic present in the brain of humans and other mammals. Since its discovery by the Hungarian psychiatrist Stephen Szára in 1956 its physiological role still remains largely unknown. A recent study performed by a Hungarian team led by Ede Frecska and Jordi Riba is the first to show that the DMT protects brain and...

Findings from the last study in a series of six Phase 2 trials of MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder (PTSD) was published today in the Journal of Psychopharmacology. The clinical trial in Boulder, Colorado (MP-12) enrolled 28 participants suffering from chronic PTSD. Results showed that after 2 - 3 sessions of MDMA psychotherapy (with active doses of...

From October 17 to December 5, host Bia Labate, Ph.D., and leading researchers are providing a psychedelic science education webinar online. Join MAPS for the first Psychedelic Science Webinar Series and you can discover all of the latest research into the therapeutic and other medicinal uses of various psychedelics including: Ayahuasca (which contains DMT), MDMA (Ecstasy) and Psilocybin (found in...